| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Heartbeam, Inc.$0.61
-0.04 (-5.53%)
F 5Pipeline Score MedTech · Pre-Clinical
Market Cap
48.62 M
EPS
-0.56
P/E Ratio
-1.56 $
Value Trade
1.54 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.37 M
Operating CF
-3.61 M
Total Assets
3.93 M
Total Liabilities
3.29 M
Equity
635.00 K
D/E Ratio
12,345
-13.01 %
Week
-1.66 %
1 Month
-38.13 %
3 Month
-45.43 %
6 Month
-83.73 %
5 Year
-83.73 %
All Time
Cash Data
Cash Position
2.04 M
Monthly Burn
1.20 M
Runway
0 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
569.31 K
52 Week Range
0.54 - 4
% held by Insiders
12.43 %
% held by Institutions
9.27 %
Enterprise Value
46.58 M
Total Shares
55.48 M
Short %
4.39 %
Float Shares
41.28 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Heartbeam, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
Jun 30, 2026
▲Enrollment CompleteTrial
Enrollment completed in Heart Attack Detection Pilot Study ahead of schedule
heart attack detectionsource ↗
Drug Pipeline Intelligence
F5
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 5%
Micro Cap (rank 866 of 911)
Percentile RankHeartbeam, Inc. has significant pipeline risk (5/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BEAT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BEAT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BEAT▲ +14.8%on this news
HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule
HeartBeam has successfully completed enrollment for its pilot study on heart attack detection ahead of the planned schedule. This study aims to evaluate the effectiveness of their technology in identifying heart attacks. The early completion of enrollment may expedite the research process and provide valuable insights sooner.
Read more →BEAT▼ -7.7%on this newsshared move
HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition
HeartBeam has announced a strategic shift aimed at accelerating the global adoption of its ambulatory ECG signal platform. The company is also undergoing a leadership transition to support this initiative. Specific details regarding the changes and their expected impact on the business were not provided in the article.
Read more →BEATHeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home
HeartBeam, Inc. announced a peer-reviewed study published in JACC: Advances, demonstrating that its ECG device can accurately assess heart attack risk. The study involved 212 patients and showed that combining ECG data with clinical risk factors achieved an AUC of 86.5%. This advancement supports HeartBeam's plans for heart attack detection, addressing a significant market need.
Read more →BEATHeartBeam Announces Proposed Public Offering of Common Stock
HeartBeam, Inc. has announced a proposed public offering of its common stock, which will be underwritten and is intended to fund the commercialization of its FDA-cleared 12-lead synthesized ECG system. The company plans to utilize the net proceeds to enhance its cardiac technology offerings, including an extended-wear patch and AI capabilities. However, the completion of the offering is uncertain and subject to market conditions.
Read more →BEAT▼ -8.5%on this news
HeartBeam Announces First Patient Enrollments in Heart Attack Detection Pilot Study
HeartBeam, Inc. has initiated its ALIGN-ACS pilot study, enrolling the first patients to evaluate its HeartBeam System for heart attack detection. Conducted at the University Clinical Center of Serbia, the study aims to compare the HeartBeam device's performance with standard ECGs in emergency settings. This pilot is a crucial step towards expanding the device's indications and improving timely cardiac care.
Read more →BEATHeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market
HeartBeam, Inc. has announced a commercial partnership with ClearCardio, marking its first commercial customer. This collaboration will integrate HeartBeam's innovative 12-lead ECG technology into ClearCardio's cardiac prevention program, enhancing patient care and monitoring. The partnership is structured to ensure a smooth rollout and supports HeartBeam's long-term growth strategy in preventive cardiology.
Read more →BEATHeartBeam Appoints Bryan Humbarger as Chief Commercial Officer
HeartBeam, Inc. has appointed Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In his new role, Humbarger will spearhead the company's commercial strategy and lead initiatives for the limited launch of the HeartBeam System, aimed at enhancing cardiac care. His extensive experience in the MedTech sector is expected to accelerate HeartBeam's growth and market presence.
Read more →BEAT▲ +12.8%on this news
HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference
HeartBeam, Inc. will attend the JP Morgan 2026 Annual Healthcare Conference from January 12-15, 2026. The company's CEO and CFO will meet with investors to discuss their recently FDA-cleared 12-lead ECG synthesis software. This technology allows patients to obtain ECG readings from home, enhancing cardiac care convenience. A limited commercial launch is planned for Q1 2026.
Read more →BEAT▲ +36.8%on this news· ran to +122% by day 3
HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment
HeartBeam, Inc. has received FDA 510(k) clearance for its novel cable-free 12-lead ECG synthesis software, enabling at-home arrhythmia assessments. This technology captures heart signals in three dimensions, providing patients with timely ECG readings. The company plans a limited U.S. launch in Q1 2026, aiming to revolutionize cardiac care and improve heart attack detection.
Read more →BEATHeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring
HeartBeam, Inc. has appointed CEO Robert Eno to its Board of Directors, expanding the Board to nine members. This decision reflects the company's commitment to innovation as it advances towards the commercialization of its 3D ECG technology. Eno, who has over 30 years of experience in the medical technology sector, will provide critical expertise in sales and market strategies. The appointment comes after HeartBeam received FDA clearance for its technology and is preparing for further developments in cardiac health management.
Read more →BEATHeartBeam Announces Exercise and Closing of Underwriter's Over-Allotment Option for Public Offering of Common Stock Additional gross proceeds of approximately $1.5 Million Follows successful closing of $10 million underw
HeartBeam, Inc. announced the exercise of the underwriter's over-allotment option for its public offering, resulting in additional gross proceeds of approximately $1.5 million. This brings the total gross proceeds from the offering to about $11.5 million. The funding will support the company's strategic plan, focusing on growth milestones and commercial readiness. MDB Capital acted as the underwriter for the offering, which closed on February 25, 2025.
Read more →BEATsettings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a
HeartBeam, Inc. has appointed Dr. Michael R. Jaff to its board of directors, bringing in a highly respected vascular physician with extensive clinical and industry experience. Dr. Jaff's background includes roles as Chief Medical Officer at Boston Scientific and professor at Harvard Medical School. His expertise is expected to guide HeartBeam's technological advancements and regulatory approvals. The company's innovative 3D-vector electrocardiogram technology aims to enhance remote cardiac diagnostics for patients.
Read more →BEATDocument HeartBeam Appoints Ken Nelson and Mark Strome to the Board of Directors Accomplished Medical Technology Leader and Veteran Investor Bring Strategic Experience and Vision to Board
HeartBeam, Inc. has appointed Ken Nelson and Mark Strome to its board of directors, effective June 5, 2023. Ken Nelson brings over 20 years of experience in digital health and medical devices, while Mark Strome has over 40 years in investment management. Their expertise is expected to support HeartBeam's goals in advancing its innovative cardiac technology and positioning the company for future growth.
Read more →BEAT▲ +12.7%on this news
Document HeartBeam Completes $25 Million Capital Raise and Updates 2023 Strategic Focus and Financial Guidance HeartBeam to Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG
HeartBeam, Inc. has completed a $25 million capital raise, enhancing its financial position as it aims to lead in ambulatory vectorcardiography. With net proceeds of $23.2 million, HeartBeam intends to develop its HeartBeam AIMIGo system and pursue FDA 510(k) clearances, targeting commercialization in 2024. The company plans to adjust its strategic focus to prioritize clinical trials and build partnerships in the market. Financial guidance suggests no significant commercial revenue for 2023 as the company executes its strategic initiatives.
Read more →BEATBreakthrough Cardiac Health Monitoring Always by your side 1 Disclaimers This presentation contains forward - looking statements . All statements other than statements of historical fact contained in this presentation, i
HeartBeam is introducing a breakthrough portable cardiac health monitoring solution that aims to replicate the diagnostic capabilities of a 12-lead ECG. The device utilizes vectorcardiography technology, which could significantly enhance the early detection of heart conditions and improve management. Despite the innovative approach, the HeartBeam platform has not yet been evaluated or approved by the FDA for clinical use. The company has outlined a regulatory strategy to establish its technology as the gold standard in ambulatory heart monitoring.
Read more →BEATHeartBeam Announces Senior Leadership Change Robert Eno Assumes Duties of Chief Business Officer Jon Hunt to Remain Strategic Advisor Consultant to HeartBeam
HeartBeam, Inc. has announced a change in senior leadership where Robert Eno will take over the role of Chief Business Officer from Jon Hunt, who will transition to a strategic advisor. This change comes just before critical milestones, including FDA submissions for HeartBeam's AIMI and AIMIGo products. Hunt has made significant contributions to the company during his tenure and will remain closely involved in strategic discussions as a consultant. The transition is aimed at aligning the company's direction with its growing needs in cardiac technology.
Read more →BEATDocument HeartBeam Appoints Robert Eno as President Senior Medical Technology Executive to Enhance Company's Strategic and Operations Capabilities
HeartBeam, Inc. announced the appointment of Robert Eno as President, a role aimed at enhancing the company's strategic direction and commercialization of its cardiac technology. Eno brings over 28 years of experience in medical technology to the company, complementing its innovative 3D-vector electrocardiogram platform for heart attack detection. His leadership is expected to accelerate HeartBeam's growth and establish its products as new standards in ambulatory-based cardiology. Both the AIMI and AIMIGo products are currently in development and have not yet received FDA clearance.
Read more →BEAT▼ -5.3%on this news
HeartBeam Names Ken Persen as Chief Technology Officer Company Hires Cardiac Industry Veteran to Lead Technology Development
HeartBeam Names Ken Persen as Chief Technology Officer Company Hires Cardiac Industry Veteran to Lead Technology Development SANTA CLARA, Calif. - August 4, 2022 -- HeartBeam, Inc. (NASDAQ BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedici
Read more →BEATDocument HeartBeam Partners with Triple Ring Technologies to Co-Develop Telehealth Solution Device 3D Vector ECG Collection Device Slated for FDA 510k Submission in the Fourth Quarter of 2022
HeartBeam Partners with Triple Ring Technologies to Co-Develop Telehealth Solution Device 3D Vector ECG Collection Device Slated for FDA 510k Submission in the Fourth Quarter of 2022 SANTA CLARA, CA - March 10, 2022 -- HeartBeam, Inc. (NASDAQ BEAT), a developmental stage digita
Read more →BEATDocument HeartBeam Appoints Alan Baumel as Chief Operating Officer Commercial Medical Device Veteran to Lead Rollout of HeartBeam Platform Technology
HeartBeam Appoints Alan Baumel as Chief Operating Officer Commercial Medical Device Veteran to Lead Rollout of HeartBeam Platform Technology SANTA CLARA, CA - December 22, 2021 -- HeartBeam, Inc. (NASDAQ BEAT), a developmental stage digital healthcare company with a proprietary
Read more →BEATHeartBeam Announces Pricing of $16.5 Million Initial Public Offering SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc . (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemed
Announces Pricing of $16.5 Million Initial Public Offering SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease,
Read more →Competitive Position
How BEAT ranks across every disease it competes inCompetitive Position is a premium feature
See how BEAT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial